Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

• Changes in clusterin, matrix metalloproteinase (MMP)-2, and MMP-9 levels [ Time Frame: Baseline to post-treatment ] [ Designated as safety issue: No ]
  Will be compared between intervention groups using a two-group t-test with a 0.05 two-sided significance level; with a sample size of 23 patients per group, there will be over 90% power to detect a difference equal to an effect size of 1.0. If the distributions are not symmetrical, a non-parametric Wilcoxon test will be considered. Correlations among the various biomarkers, as well as between post-intervention EGCG concentrations and changes in biomarker levels, will be explored (using Pearson or Spearman Rank correlation coefficients as appropriate).
• Changes in Serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein-3 [ Time Frame: Baseline to post-treatment ] [ Designated as safety issue: No ]
  Will be compared between intervention groups using a two-group t-test with a 0.05 two-sided significance level; with a sample size of 23 patients per group, there will be over 90% power to detect a difference equal to an effect size of 1.0. If the distributions are not symmetrical, a non-parametric Wilcoxon test will be considered. Correlations among the various biomarkers, as well as between post-intervention EGCG concentrations and changes in biomarker levels, will be explored (using Pearson or Spearman Rank correlation coefficients as appropriate).
• Change in ratio of 8OHdG:dG [ Time Frame: Baseline to post-treatment ] [ Designated as safety issue: No ]
  Statistical analysis will focus on the change scores (defined as changes from baseline to post-intervention). Changes in the Polyphenon E group will be compared with those in the placebo group, using a two-sided t-test.
• Change in plasma levels of EGCG [ Time Frame: Baseline to post-treatment ] [ Designated as safety issue: No ]
  Will be compared between groups, and the correlation of plasma and prostate tissue levels will be examined; however, plasma levels are expected to be low because of the washout during pre-operative fasting. Additional exploratory analyses will investigate the correlation of EGCG tissue levels with adherence during the intervention period (assessed primarily by capsule counts).

• Clusterin, matrix metalloproteinase (MMP)-2, and MMP-9 levels
• Serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein-3
• Ratio of 8OHdG:dG

Green tea extract contains ingredients that may prevent or slow the growth of prostate cancer. This phase I trial is studying how well green tea extract works in treating patients with prostate cancer undergoing surgery to remove the prostate

PRIMARY OBJECTIVES:

I. Determine the bioavailability of defined green tea catechin extract in prostate tissue after treatment with defined green tea extract in patients with prostate cancer.

SECONDARY OBJECTIVES:

I. Determine the effect of this treatment on changes in clusterin levels and matrix metalloproteinase (MMP)-2 and MMP-9 in prostate tissue from these patients.

II. Determine the effect of this treatment on changes in serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 in these patients.

III. Determine the effect of this treatment on changes in oxidative DNA damage in peripheral blood leukocytes in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive oral defined green tea catechin extract daily for 4-7 weeks.

Arm II: Patients receive oral placebo daily for 4-7 weeks.

All patients undergo surgery one day after the last dose of study agent.

Biopsies are taken at the time of surgery. Plasma and tissue catechin levels are measured with high performance liquid chromatography (HPLC). 8OHdG levels in peripheral blood are measured with HPLC and mass spectometry. Immunohistochemistry is used to measure matrix metalloproteinase (MMP)-2, MMP-9, and clusterin. Insulin-like growth factor (IGF)-1 and IGF binding protein-3 are measured with immunoenzyme techniques.

• Adenocarcinoma of the Prostate
• Stage I Prostate Cancer
• Stage II Prostate Cancer

• Dietary Supplement: defined green tea catechin extract
  Given orally
  Other Name: Polyphenon E
• Drug: placebo
  Given orally
  Other Name: PLCB
• Other: immunohistochemistry staining method
  Correlative studies
  Other Name: immunohistochemistry
• Other: immunoenzyme technique
  Correlative studies
  Other Name: immunoenzyme techniques
• Other: laboratory biomarker analysis
  Correlative studies
• Procedure: biopsy
  Undergo biopsy
  Other Name: biopsies
• Other: mass spectrometry
  Correlative studies
• Other: high performance liquid chromatography
  Correlative studies
  Other Name: HPLC

• Experimental: Arm I (green tea catechin extract)

  Patients receive oral defined green tea catechin extract daily for 4-7 weeks.

  All patients undergo surgery one day after the last dose of study agent.

  Interventions:

  • Dietary Supplement: defined green tea catechin extract
  • Other: immunohistochemistry staining method
  • Other: immunoenzyme technique
  • Other: laboratory biomarker analysis
  • Procedure: biopsy
  • Other: mass spectrometry
  • Other: high performance liquid chromatography
• Placebo Comparator: Arm II (placebo)

  Patients receive oral placebo daily for 4-7 weeks.

  All patients undergo surgery one day after the last dose of study agent.

  Interventions:

  • Drug: placebo
  • Other: immunohistochemistry staining method
  • Other: immunoenzyme technique
  • Other: laboratory biomarker analysis
  • Procedure: biopsy
  • Other: mass spectrometry
  • Other: high performance liquid chromatography

Criteria:

• Biopsy-proven adenocarcinoma of the prostate meeting the following criteria: organ-confined disease; treatable by prostatectomy
• PSA < 50 ng/mL
• ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%
• Bilirubin normal
• AST and ALT normal
• Creatinine normal
• Fertile patients must use effective contraception
• No uncontrolled intercurrent illness including, but not limited to, any of the following: ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; psychiatric illness or social situations that would limit study compliance
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extract
• No prior therapy for prostate cancer (i.e., hormone therapy, radiation therapy, or surgery)
• No systemic treatment (chemotherapy) and/or radiation therapy for any malignancy within the past 5 years (excluding nonmelanoma skin cancer or cancer confined to organs with surgical removal as the only treatment)
• No regular tea consumption (> 6 servings of hot tea or 12 servings of iced tea or equivalent combination per week) within the past month
• No other concurrent investigational agents
• No other concurrent consumption of tea or tea-derived products from green, black, or oolong tea